丹娜-法伯癌症研究所哈佛医学院医学临床路径医学主任

哈佛医学院助理教授

【专长领域】

小细胞肺癌

非小细胞肺癌

间皮瘤

胸腺肿瘤

【教育背景】专科培训

布朗大学医学院取得医学博士学位。随后，他在Beth Israel Deaconess医学中心完成内科住院医师，并在Dana-Farber / Partners CancerCare完成医学肿瘤学研究。

【学术著作】(摘选)

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, J?nne PA. J Thorac Oncol. 2015 Dec;10(12):1726-35.

在患有KRAS突变肺癌的吸烟者和从不吸烟者中表达 PD-1 及其配体PD-L1 和 PD-L2。

A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.

Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S. Oncotarget. 2015 Feb 28;6(6):4527-36.

大剂量吉非替尼治疗非小细胞肺癌的软脑膜转移的 I 期试验。

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.

Jackman DM, Miller VA, Cioffredi LA, Yeap BY, J?nne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Clin Cancer Res. 2009 Aug 15;15(16):5267-73.

表皮生长因子受体和 KRAS 突变对以前未治疗的非小细胞肺癌患者临床结果的影响: 临床试验的在线肿瘤登记结果。

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.

Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, J?nne PA. Cancer. 2008 Aug 15;113(4):808-14.

厄洛替尼联合贝伐单抗治疗恶性胸膜间皮瘤

Small-cell lung cancer.

Jackman DM, Johnson BE. Lancet. 2005 Oct 15-21;366(9494):1385-96. Review.

小细胞肺癌